Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance Tarceva in Locally Advanced Head and Neck Cancer
NCT00750555Phase 2Terminated
- Sponsor
- Geisinger
- Start
- Sep 2008
- Primary completion
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in head and neck squamous cell carcinoma (HNSCC), sponsored by Geisinger. Primary endpoint: One Year Disease Free at 1 year. Started Sep 2008; status: terminated.
02
Drugs
erlotinib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00750555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00750555.